...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: One More Promissory Note-Aug 9/24

Still no direct funding to Resverlogix.

 

Koo

Share
New Message
Please login to post a reply